Gihong Park

Gihong Park

Auto-generated profile, based on publicly available information

Gihong Park

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2023 in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Verified
Journal Article
Open access
PDF file
GPGihong Park
Gihong Park
BKBokyung Kim
Bokyung Kim
HCHyunsoo Chung
Hyunsoo Chung
SKSang Gyun Kim
Sang Gyun Kim
SCSoo-Jeong Cho
Soo-Jeong Cho
Objectives: The A2142G and A2143G mutations in the 23S ribosomal ribonucleic acid (rRNA) of Helicobacter pylori are the most common mutations associated with clarithromycin resistance. This study aimed to determine the differences in H. pylori eradication rates in patients infected with bacteria carrying the A2142G and A2143G mutations who were treated with clarithromycin-based triple therapy. Methods: Data from a previous randomized controlled trial were analyzed retrospectively. Eradication rates were compared based on the presence of H. pylori carrying the A2142G and A2143G mutations. A meta-analysis was also conducted of relevant studies containing data regarding patients who received clarithromycin-based therapy due to infections with H. pylori harboring 23S rRNA mutations. Results: No significant difference was observed in H. pylori eradication rates between patients infected with wild-type bacteria (95.7% [44/46]) compared with those infected with bacteria carrying the A2142G mutation (100.0% [3/3]; p>0.9). However, the eradication rate was significantly lower for patients infected with bacteria carrying the A2143G mutation (16.7% [1/6]; p<0.001) than for those infected with wild-type bacteria or bacteria with the A2142G mutation (100.0% [3/3]; p=0.048). In the meta-analysis, the between-group comparisons yielded similar results. Although patients infected with bacteria having the A2142G mutation exhibited no significant risk difference (RD) for eradication compared with those infected with wild-type bacteria (RD=-0.05 [-0.18 to 0.08]; I2=0%; p=0.42), those infected with bacteria having the A2143G mutation demonstrated a lower H. pylori eradication rate compared with patients infected with either wild-type (RD=0.72 [0.64–0.80]; I2=0%; p<0.001) or A2143G mutant bacteria (RD=0.76 [0.61–0.91]; I2=0%; p< 0.001). Conclusions: The A2143G mutation may play a more significant role in clarithromycin triple therapy H. pylori eradication failure than does the A2142G mutation. Additionally, H. pylori strains with the A2142G mutation can be treated effectively with clarithromycin-based triple therapy.

17 September 2025 in Gut and Liver
Verified
Journal Article
Open access
PDF file
GPGihong Park
Gihong Park
BKBONGSEONG KIM
BONGSEONG KIM
KHKyungdo Han
Kyungdo Han
HCHyunsoo Chung
Hyunsoo Chung
Gihong Park, Bongseong Kim, Kyungdo Han, Hyunsoo Chung. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250109

1 January 2025 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
SYSoyoung Yun
Soyoung Yun
BKBokyung Kim
Bokyung Kim
GPGihong Park
Gihong Park
JRJi Kon Ryu
Ji Kon Ryu
HCHyunsoo Chung
Hyunsoo Chung
Yun S, et al. J Gastric Cancer. 2025 Jul;25:e37. https://doi.org/10.5230/jgc.2025.25.e37